Analyst Price Targets — PEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 6, 2026 12:46 pm | Vijay Kumar | Evercore ISI | $320.00 | $317.90 | TheFly | Penumbra price target lowered to $320 from $335 at Evercore ISI |
| May 7, 2026 12:06 pm | Vijay Kumar | Evercore ISI | $335.00 | $325.24 | TheFly | Penumbra price target lowered to $335 from $345 at Evercore ISI |
| February 26, 2026 3:48 pm | Priya Sachdeva | UBS | $374.00 | $340.24 | StreetInsider | UBS Reiterates Neutral Rating on Penumbra (PEN) Following Q4 Results |
| February 25, 2026 7:48 pm | — | Evercore ISI | $360.00 | $338.70 | TheFly | Penumbra price target raised to $360 from $340 at Evercore ISI |
| January 20, 2026 11:34 am | — | RBC Capital | $374.00 | $350.78 | TheFly | Penumbra downgraded to Sector Perform from Outperform at RBC Capital |
| January 20, 2026 10:06 am | — | Canaccord Genuity | $374.00 | $350.78 | TheFly | Penumbra downgraded to Hold from Buy at Canaccord |
| January 16, 2026 1:55 pm | — | Jefferies | $374.00 | $350.98 | TheFly | Penumbra downgraded to Hold from Buy at Jefferies |
| January 16, 2026 7:55 am | David Rescott | Robert W. Baird | $374.00 | $350.49 | StreetInsider | Baird Downgrades Penumbra (PEN) to Neutral |
| January 16, 2026 7:12 am | Mike Kratky | Leerink Partners | $374.00 | $350.49 | StreetInsider | Leerink Partners Downgrades Penumbra (PEN) to Market Perform |
| January 16, 2026 5:46 am | Richard Newitter | Truist Financial | $374.00 | $350.49 | StreetInsider | Truist Securities Downgrades Penumbra (PEN) to Hold |
Latest News for PEN
Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
ALAMEDA, Calif., July 7, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.
The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the groundwork for…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PEN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.